Hypertension
📧 Sign up to get email alerts when something new happens for Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-12-02Clinical Trial Update: Management of Uncontrolled Hypertension (HTN) [NA]
Clinical trial update for a study on management of uncontrolled hypertension has terminated; results posted in 2022-12-02.
-
FDA approval · 2022-12-01FDA Approved: BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved a supplemental application for the combination drug Bisoprolol Fumarate and Hydrochlorothiazide by Unichem Pharmaceuticals (USA…
-
CLINICAL_TRIALS trial_result · 2022-12-01Clinical Trial Update: Chronic Kidney Disease Clinical Decision Support [NA]
A completed clinical trial on a Chronic Kidney Disease Clinical Decision Support tool with results posted in 2022, spanning chronic kidney d…
-
CLINICAL_TRIALS withdrawal · 2022-11-23Clinical Trial Update: A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease. [Phase 3]
Phase 3 trial of aprocitentan for uncontrolled blood pressure in chronic kidney disease was withdrawn.
-
FDA approval · 2022-11-18FDA Approved: NIFEDIPINE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approves Alembic Pharmaceuticals Inc.'s nifedipine under an original ANDA, authorizing a generic nifedipine product.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-11-16Clinical Trial Update: The PCORnet Blood Pressure Home Monitoring Study [NA]
Clinical trial update for the PCORnet Blood Pressure Home Monitoring Study (NCT03796689) completed with results posted in 2022.
-
FDA approval · 2022-11-14FDA Approved: NEBIVOLOL — Original Application (Lifestar Pharma LLC)
FDA approves Nebivolol as a generic drug under an original ANDA from Lifestar Pharma LLC.
-
CLINICAL_TRIALS trial_result · 2022-11-09Clinical Trial Update: Stroke Telemedicine Outpatient Prevention Program for Blood Pressure Reduction [NA]
A completed clinical trial evaluated a stroke telemedicine outpatient program aimed at reducing blood pressure for stroke prevention.
-
CLINICAL_TRIALS trial_result · 2022-11-04Clinical Trial Update: Preventing Hypertension and Sympathetic Overactivation by Targeting Phosphate [Phase 2]
Phase 2 clinical trial update investigating targeting phosphate to prevent hypertension and sympathetic overactivation.
-
FDA approval · 2022-11-04FDA Approved: BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE — Original Application (Viona Pharmaceuticals Inc)
The FDA approves an original application for a generic fixed-dose combination of bisoprolol fumarate and hydrochlorothiazide for hypertensio…
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Cardiac Neuromodulation Therapy (CNT) "Washout" Sub-Study [Phase 1, Phase 2]
Clinical trial update for Cardiac Neuromodulation Therapy washout sub-study (Phase 1/Phase 2) by BackBeat Medical; current status is unknown…
-
FDA approval · 2022-11-02FDA Approved: NEBIVOLOL — Supplemental Application (Solco Healthcare US, LLC)
The FDA approved a supplemental application for Nebivolol from Solco Healthcare US, LLC, enabling a generic Nebivolol product.
-
FDA approval · 2022-11-01FDA Approved: IRBESARTAN — Supplemental Application (AvKARE)
FDA approved AvKARE's supplemental application for IRBESARTAN (irbesartan).
-
CLINICAL_TRIALS trial_result · 2022-11-01Clinical Trial Update: Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes [Phase 4]
Phase 4 trial evaluating SGLT2 inhibitors for reduction of blood pressure by inhibiting urinary angiotensinogen in patients with type 2 diab…
-
FDA approval · 2022-10-25FDA Approved: METOLAZONE — Original Application (Aarkish Pharmaceuticals NJ Inc.)
FDA approved the original application for metolazone from Aarkish Pharmaceuticals NJ Inc., granting clearance to manufacture and market a ge…
-
FDA approval · 2022-10-24FDA Approved: METOLAZONE — Original Application (Ingenus Pharmaceuticals LLC)
FDA approves Metolazone via Original Application for a generic version by Ingenus Pharmaceuticals LLC. The approval supports its use for ede…
-
FDA approval · 2022-10-21FDA Approved: PRAZOSIN HYDROCHLORIDE — Original Application (Biocon Pharma Inc.)
FDA approved the original ANDA for prazosin hydrochloride from Biocon Pharma Inc., enabling a generic version of the antihypertensive medica…
-
CLINICAL_TRIALS trial_result · 2022-10-20Clinical Trial Update: Firibastat in Treatment-resistant Hypertension [Phase 3]
Phase 3 clinical trial update for firibastat in treatment-resistant hypertension has completed.
-
CLINICAL_TRIALS trial_result · 2022-10-18Clinical Trial Update: Multicenter Endoscopic Sleeve Gastrectomy (ESG) Trial (MERIT Trial) [NA]
The MERIT multicenter trial evaluating endoscopic sleeve gastrectomy for obesity-related indications has completed with results posted in 20…
-
FDA approval · 2022-10-17FDA Approved: FUROSEMIDE — Original Application (Rising Pharma Holdings, Inc.)
The FDA approved Rising Pharma Holdings, Inc.'s original ANDA for furosemide, authorizing a generic version of this diuretic.
-
CLINICAL_TRIALS trial_result · 2022-10-12Clinical Trial Update: Rosuvastatin/Amlodipine vs Atorvastatin/Amlodipine in Hypertension Patient With Dyslipidemia [Phase 4]
Phase 4 trial comparing rosuvastatin/amlodipine vs atorvastatin/amlodipine in patients with dyslipidemia and hypertension; study completed.
-
FDA approval · 2022-10-06FDA Approved: AMLODIPINE AND ATORVASTATIN — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved Mylan Pharmaceuticals' supplemental application for a generic fixed-dose combination of amlodipine and atorvastatin (amlodi…
-
FDA approval · 2022-10-06FDA Approved: NIFEDIPINE — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for nifedipine from Ascend Laboratories, LLC, updating the existing nifedipine product.
-
FDA approval · 2022-10-03FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved a supplemental application for Losartan Potassium from Unichem Pharmaceuticals (USA), Inc. under ANDA 203030.
-
CLINICAL_TRIALS trial_result · 2022-09-29Clinical Trial Update: Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension [Phase 4]
Phase 4 clinical trial update examining sympathoinhibition as a preferred second-line treatment for obesity-related hypertension.